NCT03946748View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

June 9, 2021

Study Completion Date

June 10, 2021

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

REGN3918

Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).

Trial Locations (12)

1083

Regeneron Study Site, Budapest

4400

Regeneron Study Site, Kaposvár

15586

Regeneron Study Site, Kota Bharu

20400

Regeneron Study Site, Kuala Terengganu

96000

Regeneron Study Site, Sibu

Unknown

Regeneron Study Site, Shatin

03080

Regeneron Study Site, Seoul

03722

Regeneron Study Site, Seoul

05030

Regeneron Study Site, Seoul

06351

Regeneron Study Site, Seoul

07985

Regeneron Study Site, Seoul

ML60JS

Regeneron Study Site, Airdrie

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03946748 - Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Biotech Hunter | Biotech Hunter